NEW YORK (AP) \u2014 A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma\u2019s latest deal to settle thousands of lawsuits over the toll of opioids that includes some money for thousands of victims of the epidemic.<\/p>\n
The deal overseen by U.S. Bankruptcy Judge Sean Lane would require members of the Sackler family who own the company to contribute up to $7 billion over 15 years. The new agreement replaces one the U.S. Supreme Court rejected last year, finding it would have improperly protected members of the family against future lawsuits. The judge said he would explain his decision in a hearing on Tuesday.<\/p>\n
It’s among the largest in a series of opioid settlements brought by state and local governments against\u00a0drugmakers,\u00a0wholesalers\u00a0and\u00a0pharmacies. It could close a long chapter \u2014 and maybe the entire book \u2014 on a legal odyssey over efforts to hold the company to account for its role in an opioid crisis connected to 900,000 deaths in the U.S. since 1999, including from heroin and illicit fentanyl.<\/p>\n
Lawyers and judges involved have described it as one of the most complicated bankruptcies in U.S. history. Ultimately, attorneys representing Purdue, cities, states, counties, Native American tribes, people with addiction and others were nearly unanimous in urging the judge to approve the bankruptcy plan for Purdue, which filed for protection six years ago as it faced lawsuits with claims that grew to trillions of dollars.<\/p>\n
Purdue lawyer Marshall Huebner told the judge that he wishes he could \u201cconjure up $40 trillion or $100 trillion to compensate those who have suffered unfathomable loss.\u201d But without that possibility, he said: \u201cThe plan is entirely lawful, does the greatest good for the greatest number in the shortest available timeframe.\u201d<\/p>\n
The opposition is much quieter this time around<\/p>\n
The saga\u00a0has been emotional\u00a0and full of contentious arguments between the many\u00a0groups that took Purdue to court, often exposing a possible mismatch between the quest for justice and the practical role of bankruptcy court.<\/p>\n
The\u00a0U.S. Supreme Court rejected a previous deal\u00a0because it said it was improper for Sackler family members to receive immunity from lawsuits over opioids.\u00a0In the new arrangement, entities who don’t opt into the settlement can sue them. Family members are collectively worth billions, but much of their assets are held in trusts in offshore accounts that would be hard to access through lawsuits.<\/p>\n
This time, the government groups involved have reached an even fuller consensus and there’s been mostly subdued opposition from individuals. Out of more than 54,000 personal injury victims who voted on whether the plan should be accepted. just 218 said no. A larger number of people who are part of that group didn’t vote.<\/p>\n
Unlike with other proceedings, there were no protests outside the courthouse.<\/p>\n
A handful of objectors spoke during the three-day hearing, sometimes interrupting the judge. Some said that only the victims, not the states and other government entities, should receive the funds in the settlement. Others wanted the judge to find the members of the Sackler family criminally liable \u2014 something Lane said is beyond the scope of the bankruptcy court, but that the settlement doesn’t bar prosecutors from pursuing.<\/p>\n
A Florida woman whose husband struggled with addiction after being given OxyContin following an accident told the court that the deal isn’t enough.<\/p>\n
\u201cThe natural laws of karma suggest the Sacklers and Purdue Pharma should pay for what they have done,\u201d Pamela Bartz Halaschak said via video.<\/p>\n
Deal would be among the biggest opioid settlements<\/p>\n
A flood of lawsuits filed by government entities against Purdue and other drugmakers, drug wholesalers and pharmacy chains began about a decade ago.<\/p>\n
Most of the major ones have\u00a0already settled\u00a0for a total of about $50 billion, with most of the money going to\u00a0fight the opioid crisis. There\u2019s no mechanism for tracking where it all goes or overarching requirement to evaluate\u00a0whether the spending is effective. Those hit the hardest generally\u00a0haven\u2019t had a say.<\/p>\n
Besides contributing cash, members of the Sackler family would formally give up ownership of the company. None have been on its board or received payments since 2018. Unlike a\u00a0similar hearing four years ago, none were called to testify in this week’s hearing.<\/p>\n
The company would get a name change \u2014 to Knoa Pharma \u2014 and new overseers who would dedicate future profits to battling the opioid crisis. That could happen in the spring of 2026.<\/p>\n
Family members would be barred from involvement in companies that sell opioids anywhere in the world. And they would not have their names added to institutions in exchange for charitable contributions.\u00a0The name has already been removed from museums and universities.<\/p>\n
Company documents, including many that would normally be subject to lawyer-client privilege, are to be made public.<\/p>\n
Some people hurt by Purdue\u2019s opioids would receive some money<\/p>\n
Unlike the other major opioid settlements, individuals harmed by Purdue\u2019s products would be in line for some money as part of the settlement. About $850 million would be set aside for them, with more than $100 million of that amount carved out to help children born dealing with opioid withdrawal.<\/p>\n
All of money for the individual victims would be delivered next year.<\/p>\n
About 139,000 people have active claims for the money. Many of them, however, have not shown proof that they were prescribed Purdue\u2019s opioids and will receive nothing. Assuming about half of the individual claimants would qualify, lawyers expect that those who had prescriptions for at least six months would receive about $16,000 each and those who had them more briefly would get around $8,000, before legal fees that would reduce what people actually receive.<\/p>\n
One woman who had a family member suffer from opioid addiction told the court by video Thursday that the settlement doesn’t help people with substance use disorder.<\/p>\n
\u201cTell me how you guys can sleep at night knowing people are going to get so little money they can\u2019t do anything with it,\u201d asked Laureen Ferrante of Staten Island, New York.<\/p>\n
Christopher Shore, a lawyer representing a group of individual victims, said in court Friday that the settlement is a better deal than taking on Sackler family members in court. \u201cSome Sacklers are bad people,\u201d he said, \u201cbut the reality is that sometimes bad people win in litigation.\u201d<\/p>\n
Most of the money is to go to state and local governments to be used in their efforts to mitigate damage of the opioid epidemic.\u00a0Overdose death numbers have been dropping\u00a0in the past few years, a decline experts believe is partly due to the impact of settlement dollars.<\/p>\n
___<\/p>\n
This article has been corrected to remove a reference to lawyers for Sackler family members asking a judge to approve the settlement.<\/p>\n","protected":false},"excerpt":{"rendered":"
NEW YORK (AP) \u2014 A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma\u2019s<\/p>\n","protected":false},"author":3,"featured_media":2255,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[7,48],"tags":[],"class_list":["post-2254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-us"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/posts\/2254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2254"}],"version-history":[{"count":1,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/posts\/2254\/revisions"}],"predecessor-version":[{"id":2256,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/posts\/2254\/revisions\/2256"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=\/wp\/v2\/media\/2255"}],"wp:attachment":[{"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.cedritech.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}